Prospective, Observational Study of Aflibercept Use in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer: A Real-World Effectiveness Study
A Durbajło, M Świeżyński, B Ziemba… - Cancers, 2024 - mdpi.com
Simple Summary The VELOUR randomized phase III trial established aflibercept (an anti-
angiogenic targeting VEGF-A, VEGF-B, and placenta growth factor) combined with FOLFIRI …
angiogenic targeting VEGF-A, VEGF-B, and placenta growth factor) combined with FOLFIRI …
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
J Feliu, I Díez de Corcuera, JL Manzano… - Clinical and …, 2017 - Springer
Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II …
A Lapeyre-Prost, S Pernot, J Sigrand… - Annals of …, 2018 - annalsofoncology.org
Background: FOLFIRI (5FU/leucovorin/irinotecan)+ aflibercept significantly improves median
overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) in …
overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) in …
Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: a single-institution real-life experience
D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - Cancers, 2021 - mdpi.com
Simple Summary The continuum of care for mCRC might include anti-angiogenic drug as
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
Aflibercept in combination with FOLFIRI as first-line chemotherapy in patients with metastatic colorectal cancer (mCRC): a phase II study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - Elsevier
Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program
M Salgado Fernandez, MT Perez Hoyos… - Expert Opinion on …, 2015 - Taylor & Francis
Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
C Erol, MAN Sendur, I Bilgetekin… - Journal of cancer …, 2022 - journals.lww.com
Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen
significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) …
significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) …
Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
A Fernández Montes, N Martínez Lago… - Cancer …, 2019 - Wiley Online Library
Abstract Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐
aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin …
aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin …
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer
DQ Chong, M Manalo, M Imperial, P Teo… - Asia‐Pacific Journal …, 2016 - Wiley Online Library
Aim To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin
and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer …
and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer …
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled …
A Thakur, MR Chorawala, RS Patel - Critical Reviews in Oncology …, 2023 - Elsevier
Background and objective Aflibercept; a decoy receptor for vascular endothelial growth
factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin …
factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin …